Pharming Group (CHIX:PHARMA) FCF Margin % : -0.07% (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Pharming Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pharming Group's Free Cash Flow for the three months ended in Mar. 2025 was €-0.1 Mil. Pharming Group's Revenue for the three months ended in Mar. 2025 was €73.2 Mil. Therefore, Pharming Group's FCF Margin % for the quarter that ended in Mar. 2025 was -0.07%.

As of today, Pharming Group's current FCF Yield % is 0.74%.

The historical rank and industry rank for Pharming Group's FCF Margin % or its related term are showing as below:

CHIX:PHARMa' s FCF Margin % Range Over the Past 10 Years
Min: -166.22 Med: 10.29 Max: 35.89
Current: 1.58

During the past 13 years, the highest FCF Margin % of Pharming Group was 35.89%. The lowest was -166.22%. And the median was 10.29%.

CHIX:PHARMa's FCF Margin % is ranked better than
78.5% of 1000 companies
in the Biotechnology industry
Industry Median: -102.52 vs CHIX:PHARMa: 1.58

Pharming Group FCF Margin % Historical Data

The historical data trend for Pharming Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group FCF Margin % Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

32.20

10.62

9.96

-7.65

-0.87

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-13.90	-18.13	12.53	9.92	-0.07

Competitive Comparison of Pharming Group's FCF Margin %

For the Biotechnology subindustry, Pharming Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pharming Group's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Pharming Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pharming Group's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-2.474	/	283.826
	=	-0.87 %

Pharming Group's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-0.051	/	73.162
	=	-0.07 %

Pharming Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pharming Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines